Market LIVE
Published markets; coverage varies by country
Product profile · United States

CLIGAVYX

 ·  Patent Litigation & Settlement History ↓

IngredientFULVESTRANT
Application typeNDA
Application210063
Product001
Dosage formSOLUTION
RouteINTRAMUSCULAR
Strength250MG/5ML (50MG/ML)
Approval date2019-08-19
Marketing statusPrescription
Status event—
ApplicantAVYXA HOLDINGS
Product source

Current GenericRadar decision

Year2019
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2019-08-19
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

APPROVAL_YEAR_FALLBACK: current product-specific evidence does not establish a DS/DS-equivalent or all-indication exclusivity anchor. Evidence limits: complete comparison of unverified ANDA candidates against original RLD documents remains incomplete; absence of generics is not established; complete historical patent/exclusivity collection remains incomplete.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
210044 / 001FINAL_APPROVAL · FINAL_APPROVED2019-03-04—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205935 / 001FINAL_APPROVAL · FINAL_APPROVED2019-05-14—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208811 / 001FINAL_APPROVAL · FINAL_APPROVED2019-07-23—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205871 / 001FINAL_APPROVAL · FINAL_APPROVED2019-08-22—SAGENT PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207754 / 001FINAL_APPROVAL · FINAL_APPROVED2019-08-22—GLENMARK PHARMACEUTICALS INC USANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209714 / 001FINAL_APPROVAL · FINAL_APPROVED2019-11-21—HBT LABS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211422 / 001FINAL_APPROVAL · FINAL_APPROVED2020-02-07—CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209246 / 001FINAL_APPROVAL · FINAL_APPROVED2020-08-07—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211689 / 001FINAL_APPROVAL · FINAL_APPROVED2020-11-17—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211730 / 001FINAL_APPROVAL · FINAL_APPROVED2021-06-11—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215234 / 001FINAL_APPROVAL · FINAL_APPROVED2021-07-29—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213553 / 001FINAL_APPROVAL · FINAL_APPROVED2021-08-13—XIROMED PHARMA ESPANA SLNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214682 / 001FINAL_APPROVAL · FINAL_APPROVED2022-02-10—JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215077 / 001FINAL_APPROVAL · FINAL_APPROVED2022-12-22—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215169 / 001FINAL_APPROVAL · FINAL_APPROVED2023-06-30—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 15 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
210044 / 001AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2019-03-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205935 / 001SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2019-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208811 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2019-07-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205871 / 001SAGENT PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2019-08-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207754 / 001GLENMARK PHARMACEUTICALS INC USAFINAL_APPROVAL · FINAL_APPROVED2019-08-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209714 / 001HBT LABS INCFINAL_APPROVAL · FINAL_APPROVED2019-11-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211422 / 001CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTDFINAL_APPROVAL · FINAL_APPROVED2020-02-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209246 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2020-08-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211689 / 001ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2020-11-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211730 / 001APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2021-06-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215234 / 001ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-07-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213553 / 001XIROMED PHARMA ESPANA SLFINAL_APPROVAL · FINAL_APPROVED2021-08-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214682 / 001JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDFINAL_APPROVAL · FINAL_APPROVED2022-02-10 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215077 / 001ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2022-12-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215169 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2023-06-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.